---
title: Improve thinking with brain stimulation
nct_id: NCT06090682
status: RECRUITING
sponsor: Tianjin Huanhu Hospital
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06090682"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06090682"
last_fetched: "2026-05-10T14:06:51.744Z"
source: "Parkinson's Pathways (curated)"
---
# Improve thinking with brain stimulation

**Goal (in five words):** Improve thinking with brain stimulation

**Official Title:** Effect and Mechanism of Deep Brain Stimulation and Transcranial Magnetic Stimulation on Parkinson's Disease With Cognitive Impairment

**Trial ID:** [NCT06090682](https://clinicaltrials.gov/study/NCT06090682)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Tianjin Huanhu Hospital
- **Target Enrollment:** 200 participants
- **Start Date:** 2023-11-01
- **Completion Date:** 2026-11-01
- **Conditions:** Parkinson Disease, Cognitive Impairment
- **Interventions:** Deep Brain Stimulation(DBS) and Transcranial Magnetic Stimulation(TMS)
- **Intervention Types:** DEVICE

## Summary For Families

The goal is to understand whether and how deep brain stimulation and transcranial magnetic stimulation can improve thinking and the brain circuits behind cognitive decline in people with Parkinson's who have had the disease for several years. DBS implants electrodes in the subthalamic nucleus to modulate abnormal circuit activity that drives symptoms and can influence cognition, while TMS uses noninvasive magnetic pulses to boost targeted cortical networks; the study will track cognitive changes and the underlying brain mechanisms, including how these effects relate to levodopa response. They are enrolling up to 200 adults up to age 75 with Parkinson's for more than 5 years who show at least a 30% improvement with an acute levodopa dose and are candidates for STN DBS, excluding those with severe cognitive impairment, major psychiatric illness, atypical parkinsonism, or surgical contraindications.

## Eligibility

- **Maximum age:** 75 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1\. The clinical diagnosis of PD is consistent with the United Kingdom Parkinson's Disease Society Brain Bank criteria, with disease duration over 5 years, acute levodopa motor response ≥30%, and indication for STN-DBS.

Exclusion Criteria:

Exclusion criteria included patients with severe cognitive impairment, severe psychiatric disorders, acute levodopa motor response less than 30%, atypical parkinsonism, and contraindications to surgery.
```

## Locations (1)

- Tianjin Huanhu Hospital, Tianjin, Tianjin Municipality, China _(39.1422, 117.1767)_
  - Yin Shaoya, doctor — (CONTACT) — +86 18622139285 — yinsya@hotmail.com

## Central Contacts

- Zhao Guangrui, doctor — (CONTACT) — +86 18956405513 — Guangrui-Zhao@hotmail.com
- Feng Keke, doctor — (CONTACT) — +86 18920195507 — fengke1976@163.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT06090682*  
*HTML version: https://parkinsonspathways.com/trial/NCT06090682*  
*Source data: https://clinicaltrials.gov/study/NCT06090682*